Eggerthella lenta is an emerging pathogen that has been underrecognized due to historical difficulties with phenotypic identification. Until now, its pathogenicity, antimicrobial susceptibility profile, and optimal treatment have been poorly characterized. In this article, we report the largest cohort of patients with E. lenta bacteremia to date and describe in detail their clinical features, microbiologic characteristics, treatment, and outcomes. We identified 33 patients; the median age was 68 years, and there was no gender predominance. Twenty-seven patients (82%) had serious intra-abdominal pathology, often requiring a medical procedure. Of those who received antibiotics (28/33, 85%), the median duration of treatment was 21.5 days. Mortality from all causes was 6% at 7 days, 12% at 30 days, and 33% at 1 year. Of 26 isolates available for further testing, all were identified as E. lenta by both commercially available matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) systems, and none were found to harbor a vanA or vanB gene. Of 23 isolates which underwent susceptibility testing, all were susceptible to amoxicillin-clavulanate, cefoxitin, metronidazole, piperacillin-tazobactam, ertapenem, and meropenem, 91% were susceptible to clindamycin, 74% were susceptible to moxifloxacin, and 39% were susceptible to penicillin.
展开▼
机译：埃格特氏菌是一种新兴病原体，由于表型鉴定的历史困难而未能得到充分认识。迄今为止，其致病性，抗菌药敏性和最佳治疗方法尚未得到很好的表征。在本文中，我们报道了迄今为止最大的大肠杆菌大肠杆菌菌血症患者队列，并详细描述了他们的临床特征，微生物学特征，治疗和结果。我们确定了33例患者;中位年龄为68岁，没有性别优势。二十七名患者（82％）患有严重的腹内病理，通常需要医疗程序。在接受抗生素治疗的患者中（28/33，占85％），中位治疗时间为21.5天。所有原因的死亡率在7天时分别为6％，30天时为12％和1年时为33％。在可供进一步测试的26种分离物中，通过市售的基质辅助激光解吸电离-飞行时间质谱（MALDI-TOF MS）系统将所有分离物鉴定为大肠埃希氏菌，没有发现携带 vanA 或 vanB 基因。在接受药敏测试的23株菌株中，所有菌株均对阿莫西林-克拉维酸盐，头孢西丁，甲硝唑，哌拉西林-他唑巴坦，厄他培南和美罗培南敏感，其中91％对克林霉素敏感，74％对莫西沙星敏感，39％对青霉素敏感。
展开▼
